# Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

> **NCT04166318** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 252 (estimated)

## Conditions studied

- Anal Basaloid Carcinoma
- Anal Canal Cloacogenic Carcinoma
- Anal Canal Squamous Cell Carcinoma
- Anal Margin Squamous Cell Carcinoma
- Stage I Anal Cancer AJCC v8
- Stage IIA Anal Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Capecitabine
- **PROCEDURE:** Computed Tomography
- **OTHER:** Fludeoxyglucose F-18
- **DRUG:** Fluorouracil
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Mitomycin
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04166318
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-02
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166318, "Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04166318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*